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Background: Despite a number of important differences in the pathogenesis, course, and 
prognosis, asthma and chronic obstructive pulmonary disease (COPD) have many features 
in common. Furthermore, smoking induces considerable overlap in pathogenesis and clinical 
features between these conditions. This study aimed to reveal what inflammatory patterns 
prevail in clinically established diagnosis groups, including overlap phenotypes of asthma and 
COPD, and to evaluate the correlation with airway reversibility and hyperreactivity in these 
overlapping conditions.
Methods: A total of 110 patients (17 healthy subjects; 16 “healthy” smokers; 46 asthma 
patients: 24 smokers and 22 non-smokers; and 31 COPD patients: 10 COPD patients with 
reversibility and 21 without) participated in the study. Induced sputum, reversibility testing, 
methacholine and adenosine 5’monophosphate (AMP) provocation challenges, and skin prick 
testing were performed. Airways inflammation was assessed by differential cell counts, and 
cytokines (interleukin-8 [IL-8] and tumor necrosis factor-alpha [TNF-α]) were measured in 
induced sputum by enzyme-linked immunosorbent assay (ELISA).
Results: COPD patients with reversibility had increased sputum neutrophils, IL-8, and TNF-α 
levels compared to smoking asthmatics. No difference was found in inflammatory cells and 
cytokines between COPD subgroups. Sputum neutrophilia was inversely correlated with the 
change in forced expiratory volume in one second (∆FEV1) in smoking asthmatic patients 
(r = -0.563, P = 0.036). No correlation was found between airway hyperresponsiveness (AHR), 
either with methacholine or AMP, and inflammation in asthmatic patients, regardless of smoking. 
Reversibility was not correlated with inflammation in COPD patients. However, the response 
to AMP challenge was correlated with sputum neutrophils (r = 0.844, P = 0.001).
Conclusion: Although overlaps exist in the disease characteristics of asthma and COPD, the com-
bination of lung function testing, sputum induction, and AHR reveals information that   facilitates 
the distinction between these diseases, allowing clinicians to better tailor their therapy.
Keywords: asthma, COPD, smoking, lung function, airway hyperresponsiveness
Introduction
Although asthma and chronic obstructive pulmonary disease (COPD) are both defined 
by the presence of airflow obstruction; airway remodeling; and airway inflammation, 
the two conditions are clinically and pathophysiologically distinct.1–3 Studies on the 
underlying inflammation demonstrate a difference in the preponderance of inflam-
matory cells and mediators in each disease. However, in clinical practice, it has been 
recognized that a firm diagnosis between these diseases is often difficult to achieve.3–7 International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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Therefore, it is quite common to observe patients with asthma 
showing COPD-like phenotypes, and vice versa, making it 
a priority to search for optimal prevention, treatment, and 
management strategies for these cases of coexisting lung 
obstructive diseases.
Asthma most often presents at a younger age as recur-
rent episodes of increased airway obstruction that may have 
  varying frequency and intensity, which then become recog-
nized as a chronic pattern of reversible airway obstruction.1 
In a subset of patients with long-term disease, reversibility 
of airway obstruction is diminished (due to airway remod-
eling), and a disease pattern similar to COPD may ensue.4 
Furthermore, smoking affects asthma by influencing the 
underlying airway inflammatory process;8 it increases airway 
hyperresponsiveness (AHR), by the induction of airway 
inflammation and geometric changes of the airways due to 
airway smooth muscle hypertrophy, mucus hypersecretion, 
and loss of alveolar attachments.9,10 Furthermore, increases in 
neutrophils have been described, thus resulting in asthmatics 
with a COPD phenotype.
COPD is a progressive disease of declining lung function, 
observed mainly in older adults with a history of cigarette 
smoking.2 However, although it is known that COPD is an 
inflammatory response of the lungs, characterized by chronic 
airflow limitation that is not fully reversible,2 there is a sub-
group of COPD patients with reversibility, which has been 
associated with increased exhaled nitric oxide and sputum 
eosinophilia.11 COPD is often accompanied by AHR and 
smoking seems to be a risk factor for increasing AHR over 
time, whereas smoking cessation improves AHR, both in 
asthma and COPD patients.12
Based on the above data, the aim of this study was: 1) to 
look for inflammatory parameters that might distinguish 
between asthma and COPD patients; and 2) to evaluate the 
inflammatory patterns in relation to airway reversibility and 
hyperreactivity in the subgroups of asthma and COPD that 
might lead to overlapping phenotypes; namely smoking 
asthmatics, and COPD patients with reversibility.
Methods
A total of 110 patients (17 healthy subjects; 16 “healthy” 
smokers; 46 asthma patients: 24 smokers and 22   non-smokers; 
and 31 COPD patients: 10 COPD patients with reversibility 
and 21 without) participated in the study. COPD patients 
were all current smokers (.15 pack-years) and so were 
smoker asthmatics (number of pack-years = packs smoked 
per day x years as a smoker). All “healthy” smokers were 
lifelong smokers ($15 pack-years), with no history of 
lung disease, no chronic respiratory symptoms, and normal 
spirometry. Healthy non-smokers were asymptomatic and 
had no history of asthma or other respiratory disease, or any 
allergic   condition. Atopic status was assessed by skin-prick 
testing using 13 common allergens applied to the forearm. 
The allergens tested (HAL Allergen Lab B.V., Haarlem, 
Netherlands) were house dust mites (Dermatophagoides 
pteronyssinus and Dermatophagoides farinae), household 
pets (cat and dog), pollens (mixed grass, olive, mixed 
weed, and Parietaria judaica), and moulds (Alternaria and 
  Aspergillus fumigatus). Histamine and glycerinated saline 
solution were used as positive and negative controls. A skin-
prick test result was considered positive if the mean wheal 
diameter was $3 mm.
Asthma was diagnosed using the American Thoracic 
Society guidelines.1 Stable asthma was defined as no asthma 
exacerbation within the three months prior to study entry, and 
no respiratory infection or antibiotic use within the preced-
ing six weeks. No smoking asthmatic met Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) guidelines 
for Stage I disease (forced expiratory volume in one second 
(FEV1) .80% predicted; FEV1/forced vital capacity (FVC) 
ratio ,70%).
COPD patients satisfied the European Respiratory 
Society (ERS) criteria11 for COPD and were selected 
according to the GOLD13 criteria for COPD stages I and II 
(FEV1/FVC # 0.7, and FEV1 $ 0.8 and 0.5 , FEV1 , 0.8, 
respectively) and with no evidence of emphysema, based on 
  high-resolution computed tomographic scans of the lungs and 
the diffusing capacity of lung for carbon monoxide (DLCO). 
COPD patients having reversibility .9% of the predicted 
FEV1 were considered as COPD with reversibility.14,15
All participants met the following criteria: no use of 
inhaled or oral corticosteroids in the previous three months, 
and no respiratory tract infection six weeks prior to the 
study. Patients with co-morbidities, such as bronchiectases, 
  interstitial diseases, and heart failure, were excluded.
None of the healthy smokers or non-smokers were 
receiving either long-acting bronchodilators or   leukotriene 
  modifiers. Asthmatics were taking only inhaled,   short-acting, 
beta (β2) agonists on an “as needed” basis for their 
asthma. At the time of the study, all asthmatics (smokers 
or non-smokers) were in a stable clinical condition, as 
  demonstrated by the low daily variability (,15%) of peak 
flow   measurements during the two weeks prior to the study, 
and by the low   variability in FEV1 performed during the study 
measurements. Peak flow measurements were performed 
only by the group of asthmatic patients.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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Nine out of 31 COPD patients were under treatment with 
inhaled tiotropium and inhaled, short-acting, β2 agonists as 
needed. Ten were receiving inhaled, short-acting, β2 agonists 
or ipratropium as needed and none were receiving long-acting 
bronchodilators. Before each measurement, subjects were 
asked not to use long- or short-acting β2 agonists and/or 
  ipratropium for at least 12 hours prior to the tests, and tiotro-
pium for 48 hours prior to the tests.
Each subject attended the laboratory for three separate 
visits within one week. On the first visit, sputum induction 
was performed after a reversibility test. On the   second visit, 
patients underwent a methacholine provocation challenge 
and skin prick testing, and on the third visit, an adenos-
ine 5’monophosphate (AMP) provocation challenge was 
  performed. No variability was observed in FEV1 on each 
visit during baseline spirometry performed before the 
  provocation tests.
All subjects gave informed consent for their   participation 
in the study, which was approved by the Hospital ethics 
committee.
Pulmonary function and bronchial 
hyperreactivity tests
Pulmonary function (FEV1 and FEV1/FVC) was   measured with 
a dry wedge spirometer (Masterscreen, Jaeger,   Hoechberg, 
Germany) according to standardized guidelines,14 by the 
same technician, using the same spirometer.   Reversibility 
test was performed 20 minutes after inhalation of 200 µg 
  salbutamol via a metered dose inhaler. ∆FEV1 was   calculated 
as:   post-bronchodilator FEV1 minus   pre-bronchodilator 
FEV1/post-bronchodialator FEV1 3 100.
Methacholine chloride and AMP (both Sigma Chemical, 
St. Louis, MO) were dissolved in normal saline solution to 
produce doubling concentrations of 0.39–200 mg/mL for 
methacholine, and 0.04–320 mg/mL for adenosine, and 
immediately used for bronchial challenge (Masterscreen, 
Jaeger, Hoechberg, Germany).16,17 The first nebulization 
administered in each challenge was normal saline solution, 
and the post-saline solution FEV1 was used as the baseline 
for the calculation of subsequent percentage fall in FEV1. 
After challenge with saline solution, doubling concentrations 
of methacholine chloride were inhaled. Because of the effect 
of a deep inspiration on subsequent airway tone, only one 
measurement for FEV1 was performed, 60 to 90 seconds after 
inhalation of each concentration, unless the forced expiratory 
maneuvre was judged technically unsatisfactory.
The test was interrupted when a 20% decrease in FEV1 
from the post-saline solution value was recorded, or when the 
highest concentration was reached. A log dose-response curve 
was constructed for each challenge, and the   provocative dose 
of methacholine or AMP required to produce a 20% fall in 
FEV1 (PD20) was calculated by logarithmic interpolation.
Sputum induction and processing
Sputum was induced by inhalation of hypertonic saline 
aerosol and processed as described previously.18 Briefly, 
15 minutes after salbutamol inhalation (200 µg), normal 
saline (0.9%) and then hypertonic saline (3%, 4%, and 5%), 
nebulized by an ultrasonic nebulizer (ULTRA-NEB 2000, 
DeVilbiss Heathcare Inc, Somerset, USA), was inhaled for 
each concentration over a period of seven minutes. Subjects 
were encouraged to cough deeply after the seven minute 
intervals. All subjects produced an adequate aliquot of spu-
tum which was processed within two hours after termination 
of the induction. Sputum samples were transferred to a petri 
dish and the volume and macroscopic characteristics of the 
whole sample recorded. Sputum plugs were separated from 
contaminating saliva using sterile forceps. The plugs were 
placed in a pre-weighed tube and the weight recorded. The 
sputum was then diluted three-fold with phosphate buffer 
solution containing freshly prepared dithiothreitol (Sigma 
Chemical Co, Poole, UK). Final concentration was 1 mmol/L. 
The sample was vortexed briefly and incubated at 37°C for 
15 minutes with constant agitation. The suspension was 
filtered through monofilament filter cloth to remove mucus, 
centrifuged at 790 g-force for four minutes (4°C), and the 
pellet was re-suspended. Total cell counts were determined 
with a Neubauer haemocytometer (VWR International Ltd, 
Poole, UK) using tryptan blue exclusion to determine cell 
viability; dead cells and epithelial cells were excluded.
Cell smear preparations were made using a Cytospin 
3 cytocentrifuge at 500 g-force for two minutes (Shandon 
Inc., Pittsburgh, PA, USA). Sputum cytospin slides were 
stained with May-Grünwald-Giemsa for differential cell 
counts. Counting of 400 non-squamous cells took place in a 
blinded fashion by one technician. Sputum samples contain-
ing .20% of squamous cells and with cell viability ,70% 
were excluded from analysis as an indication of poor cytospin 
quality. The supernatant was stored at -80°C for subsequent 
assay for interleukin-8 (IL-8) and tumor necrosis factor-alpha 
(TNF-α) concentrations.
Measurement of IL-8 and TNF-α
The concentrations of TNF-α and IL-8 were determined by 
enzyme-linked immunosorbent assay (ELISA), using kits pur-
chased from R&D Systems (Minneapolis,   Minnesota, USA). International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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The assays were carried out according to the   manufacturer’s 
recommendations. The sensitivities of the assays used were 
1.6 pg/ml and 3.5 pg/ml respectively.
Statistical analysis
Data were expressed as mean (±SE) or median values. IL-8 
and TNF-α were expressed as the median value and the 
inter-quartile range. All calculations of PD20 were performed 
with the base-2 logarithm (log2), as this reflects doubling 
concentrations and normalizes the distribution. Patients 
already responding to saline were assigned a PD20 value half 
of the lowest concentration applied. Patients not responding 
to the highest concentration of methacholine or AMP were 
assigned a value twice the highest concentration applied. Dif-
ferences between subject groups were initially assessed using 
a Kruskal–Wallis test and if significant, a Mann–Whitney rank 
test was then performed. Correlations between inflammatory 
cells and cytokine levels in sputum, smoking characteristics, 
or lung function parameters were calculated using Spearman’s 
rank correlation tests. Statistical analysis was not influenced 
by values at the lower limits of detection, since the non-
parametric tests used were based on ranks of values. A p value 
of less than 0.05 was considered significant.
Results
All smokers were matched for smoking pack-years. The 
clinical characteristics of the subjects participating in the 
study are shown in Table 1. COPD smokers were older than 
“healthy” smokers, non-smokers, asthmatics, and smoking 
asthmatics (P , 0.05).
Sputum cells – cytokines
The median (inter-quartile range) of cell percentages and 
cytokines in sputum are shown in Table 2. Smoking asth-
matics had a significantly higher percentage of sputum 
neutrophils, and a significantly lower percentage of sputum 
eosinophils compared to non-smoking asthmatics (P , 0.05). 
This increase was less than in COPD patients. COPD patients 
with reversibility had increased neutrophils and eosinophils 
(P , 0.05) compared to asthma patients and compared to 
healthy control subjects (P , 0.05). No difference was seen 
in neutrophil and eosinophil percentages between smoking 
asthmatics and COPD patients with reversibility. Eosinophils 
were decreased in COPD patients with or without reversibil-
ity, compared to non-smoking asthmatics (P , 0.05).
A statistically significant difference in IL-8 sputum 
  levels, but not in TNF-α, was observed in asthma groups. 
The   cytokines IL-8 and TNF-α were significantly increased 
in COPD groups, whereas there was no difference in 
  inflammatory cells and cytokines between the groups.
AHR
The mean PD20 methacholine and PD20AMP values, as well 
as the number of positive and negative provocation tests, are 
shown in Table 3. There were no statistically significant dif-
ferences between groups, although more positive AMP tests 
were found in smoking groups, namely smoking asthmatics 
and COPD groups.
Correlation among reversibility, 
inflammatory cells, and mediators
Reversibility was not correlated with inflammation, as 
expressed by sputum’s inflammatory cells and cytokines IL-8 
and TNF-α in asthma and COPD groups (Table 4). However, 
∆FEV1 was inversely correlated with sputum’s neutrophils 
in smoking asthmatics (Figure 1).
Correlation among AHR, spirometry, 
inflammatory cells, and mediators
In asthma groups (non-smoking and smoking), FEV1 (% of 
predicted) was correlated with PD20methacholine (r = 0.637, 
P = 0.006 and r = 0.548, P = 0.028 respectively) and with 
PD20AMP (r = 0.527, P = 0.034 and r = 0.544, P = 0.021 
respectively).
In non-smoking asthmatics, PD20 methacholine was 
  correlated with FEV1/FVC (r = 0.641, P = 0.006) and 
Forced Expiratory Flow 25%–75% (FEF25–75) (r = 0.575, 
P = 0.05), whereas in smoking asthmatics, PD20AMP was 
  correlated with FEV1/FVC (r = 0.565, P = 0.023) and 
FEF25–75 (r = 0.538, P = 0.031). Furthermore, PD20AMP was 
  correlated with FEV1/FVC (r = 0.617, P = 0.019) and FEF25–75 
(r = 0.627, P = 0.019) in COPD patients.
The response to AMP challenge was correlated with 
sputum’s neutrophilia (r = 0.662, P = 0.004) only in COPD 
patients (Figure 2).
Discussion
The main end-point of this study was to look for inflamma-
tory parameters that might distinguish between asthma and 
COPD phenotypes in clinical practice. COPD patients with 
reversibility of airflow limitation did not differ significantly 
from smoking asthmatics. Interestingly, the percentage of 
sputum neutrophils was correlated with PD20AMP in COPD 
patients, but not in patients with asthma. This is a novel obser-
vation to the authors’ knowledge. Finally, COPD patients, 
including the sub-group of COPD patients with reversibility, International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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Table 1 Subject characteristics
Healthy 
(n = 17)
Healthy 
smokers 
(n = 16)
Asthmatics 
(n = 22)
Smoking 
asthmatics 
(n = 24)
COPD 
(n = 21)
COPD 
Reversibility 
(n = 10)
Age (yrs) 41.5 ± 3.5 40.9 ± 1.9 45.2 ± 2.2 49.4 ± 1.8 58.4 ± 2.0*# 55.2 ± 5.0*#
Smoking 
(pack-years)
0 44.6 ± 4.3 0 39.4 ± 4.6 50.7 ± 4.9 52.1 ± 5.4
FEV1 (L) 3.3 ± 0.2 3.4 ± 0.2 3.2 ± 0.2 2.7 ± 0.1*# 2.1 ± 0.2*# 2.3 ± 0.3*#
FEV1 
(% pred)
104.7 ± 3.1 102.7 ± 2.3 98.5 ± 3.5 86.1 ± 3.5*# 67.6 ± 3.3*# 66.1 ± 5.3*#
∆FEV1 1.5 ± 0.4 1.0 ± 0.2 14 ± 0.6*# 9.5 ± 1.8*# 2.8 ± 1.0†‡** 7.5 ± 1.6*#†
FVC (L) 4.2 ± 0.2 4.3 ± 0.2 4.0 ± 1.0 3.9 ± 1.2 3.7 ± 2.1*# 3.8 ± 0.3*#
FVC 
(% pred)
106.8 ± 2.4 108.3 ± 5.7 104.3 ± 3.3 97.8 ± 3.1 84.1 ± 4.3*# 89.9 ± 4.0*#
FEV1/FVC 83.0 ± 1.5 80.6 ± 1.2 78.6 ± 1.5 72.3 ± 2.1*# 63.9 ± 1.9*#†‡ 59.98 ± 2.9*#†‡
FEF25–75 (L) 3.6 ± 0.4 3.3 ± 0.3 3.2 ± 0.3 2.1 ± 0.2*#† 1.1 ± 0.1*# 1.4 ± 0.3*#
FEF25–75 
(% pred)
92.0 ± 7.9 82.5 ± 4.9 77.1 ± 5.7 55.8 ± 5.2*#† 33.2 ± 2.4*#†‡ 30.5 ± 3.2*#†‡
RV  
(% pred)
99.1 ± 4.8 90.9 ± 3.5 102.0 ± 10.1 106.0 ± 5.7 94.2 ± 8.7 96.5 ± 5.3
TLC 
(% pred)
94.4 ± 2.6 96.5 ± 2.4 91.5 ± 3.0 92.7 ± 2.6 84.2 ± 5.2 90.6 ± 4.8
FRC 
(% pred)
94.2 ± 4.9 96.2 ± 5.3 84.6 ± 6.0 91.4 ± 4.4 99.6 ± 4.3 103.2 ± 5.7
DLCO 
(% pred)
98.0 ± 5.0 82.9 ± 3.7 103.5 ± 4.5 95.1 ± 3.0 77.9 ± 5.4*† 78.5 ± 5.9*†
Notes: Values are expressed as mean ± SE. *denotes a significant difference vs healthy subjects; #vs healthy smokers; †vs asthmatics; ‡vs smoking asthmatics; and **vs COPD 
with reversibility (P , 0.05).
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; FEF25–75, forced expiratory flow 
25–75; RV, residual volume; TLC, total lung capacity; FRC, forced residual capacity; DLCO, diffusing lung capacity for carbon monoxide.
Table 2 Patterns of inflammatory markers within clinical diagnosis groups
Healthy 
(n = 17)
Healthy 
smokers 
(n = 16)
Asthmatics 
(n = 22)
Smoking 
asthmatics 
(n = 24)
COPD 
(n = 21)
COPD 
Reversibility 
(n = 10)
Neutrophils % 41.3 
(12.0–79.5)
47.4 
(19.1–1.3)
22.5 
(0.5–66.3)
50.1† 
(3.6–90.9)
67.9*#† 
(16.8–92.5)
69.2*#† 
(17.3–86.3)
Eosinophils % 0.90 
(0.3–6.5)
0.35 
(0.1–2.1)
3.9*# 
(1.5–18.0)
1.5#† 
(0.3–20.8)
1.00† 
(0.2–3.4)
1.9#† 
(0.7–4.5)
IL-8 (pg/ml) 750 
(280–46176)
1130 
(90–30570)
6410*# 
(727–9520)
10159*#† 
(194–61776) 
20370*#†‡ 
(5090–64100)
19130*#†‡ 
(7480–39410)
TNF-α (pg/ml) 13.7 
(1.5–34.8)
19.7 
(6.8–76.4)
6.7*# 
(1.5–37.7) 
7.7# 
(22.5–139.2)
50.6*#†‡ 
(2.6–90.3)
47.9#†‡ 
(22.5–139.2)
Notes: Values are expressed as median values (inter-quartile range). *denotes a significant difference vs healthy subjects; #vs healthy smokers; †vs asthmatics; and ‡vs smoking 
asthmatics (P , 0.05).
Abbreviations: IL-8, interleukin-8; TNF-α, tumor necrosis factor-alpha.
had significantly increased sputum IL-8 and TNF-α levels 
compared to smoking asthmatics.
The increased percentage of neutrophils in smoking 
asthmatics was not significantly different to that in COPD 
smokers. However, percentage of sputum neutrophils was 
inversely correlated with ∆FEV1 in smoking asthmatics, but 
not in COPD smokers or COPD patients with reversibility.
The inflammatory pattern in induced sputum of   smoking 
patients with asthma and COPD has been   previously 
studied.19–22 Our findings are in keeping with those of 
Boulet et al who observed an increase in total cells and 
neutrophils in induced sputum of smoking asthmatics,21 and 
with those of Chalmers et al, who observed a significant 
decrease in sputum eosinophils in smoking asthmatics.22 
The reasons for the reduction in eosinophils have not yet 
been elucidated. It is suggested that exogenous nitric oxide 
(NO) in cigarette smoke increases the apoptosis of activated 
eosinophils.23,24 Furthermore, it has been shown that nicotine International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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within tobacco smoke exerts secondary immunomodulatory 
effects on eosinophil function, by inhibiting the release of 
pro-  inflammatory cytokines from macrophages.25,26
Interestingly, an inverse relationship between ∆FEV1 
and the percentage of neutrophils in sputum of smoking 
asthmatics was shown, ie, the higher the sputum   neutrophil 
count the lower the reversibility in currently smoking, 
steroid-naive, asthmatic patients. This finding is additive to 
the findings of previous studies, suggesting that neutrophilic 
inflammation contributes to irreversible airflow obstruction 
in asthma. Indeed, Shaw et al27 have previously shown that 
post-bronchodilator FEV1 is associated with sputum neu-
trophils. Increased sputum neutrophil count was associated 
with lower pre-bronchodilator FEV1, but to a lesser extent 
compared to the differential eosinophil count. Earlier studies 
have also shown a relationship between sputum neutrophils 
and FEV1. Woodruff et al28 demonstrated a relationship 
between airway neutrophilia and persistent airflow limita-
tion in asthma. After correcting for confounding factors, 
their analysis demonstrated that increased sputum neutrophil 
percentage was independently associated with lower FEV1, 
but not with PC20 (the concentration of the agonist leading 
to a fall in FEV1 of 20%).
A study by Little et al29 also demonstrated that maxi-
mal FEV1 was inversely correlated with the duration of 
disease and sputum neutrophils. Since we did not find any 
  correlation between neutrophil count in sputum and FEV1 
in non-smoking asthmatics, our data suggest that smoking-
induced neutrophilia might be an important mediator of 
airway narrowing in asthma. Indeed, neutrophils and their 
products could contribute to airway narrowing in asthma 
in several ways. Neutrophils might cause airway narrowing 
secondary to mucus hypersecretion, either indirectly, through 
the production of mediators such as neutrophilic elastase, or 
directly, through direct goblet cell/neutrophil interaction.29,30 
In addition, neutrophil products might be important mediators 
of epithelial cell activation.31 Finally, neutrophil products can 
activate eosinophils.32 However, although neutrophils might 
exert specific effects on the airways, leading to chronic air-
way narrowing as a downstream effect of tissue injury, it is 
less clear if they release pro-inflammatory or pro-fibrotic 
cytokines.
The fact that we did not find any correlation between 
  sputum neutrophil or sputum eosinophil percentages 
and ∆FEV1, in COPD patients or COPD patients with 
  reversibility, is not peculiar. Papi et al11 also found increased 
sputum eosinophils in COPD with reversibility, but the 
reversibility of airflow limitation, expressed as   percentage 
of predicted or absolute increase in FEV1 after inhaled 
salbutamol, did not correlate with any sputum inflammatory 
cell type. Furthermore, Gross et al33 showed that greater 
bronchodilator responses occurred in COPD patients with 
pre-bronchodilator FEV1 values ,55% of predicted, and 
were associated with cholinergic tone that was increased in 
proportion to the severity of airway obstruction. Therefore, 
it seems that the extent of bronchodilator response in COPD 
is not related to airway inflammation.
In this study, it was demonstrated that PD20   methacholine 
and PD20AMP levels are both associated with baseline 
FEV1 (% pred) in asthma groups, regardless of smok-
ing habits. A positive correlation between the severity of 
bronchial hyperresponsiveness and FEV1 has been previ-
ously observed.34 This could be explained by the fact that 
a given stimulus will result in a larger bronchoconstrictor 
response in a subject with more severe airway obstruction 
than in a subject with less severe obstruction, resulting in a 
lower provocative concentration causing a 20% reduction 
in FEV1.34,35 Moreover, in non-smoking asthmatics, PD20 
methacholine was positively correlated with FEV1/FVC and 
FEF25–75, whereas in smoking asthmatics and COPD patients, 
Table 4 Correlations between reversibility, inflammatory cells, 
and mediators
Asthmatics 
(n = 22)
Smoking 
asthmatics 
(n = 24)
COPD 
(n = 31)
∆FEV1 r P value r P value r P value
Eosinophils  0.47 0.06 0.17 0.49 -0.11 0.67
Neutrophils  0.13 0.65 -0.56 0.04 0.15 0.49
IL-8 0.33 0.42 0.48 0.85 -0.18 0.43
TNF-α 0.56 0.92 0.22 0.32 0.70 0.76
Abbreviations: ∆FEV1, change in forced expiratory volume in one second; IL-8, 
interleukin-8; TNF-α, tumor necrosis factor-alpha.
Table 3 PD20meth and PD20AMP in clinical diagnosis groups
Asthmatics 
(n = 22) 
Smoking 
asthmatics 
(n = 24)
COPD 
(n = 21)
COPD 
Reversibility 
(n = 10)
PD20meth  
(mcg)(+/-)
533.1 ± 345.5 
(13/4)
513.5 ± 322.7 
(11/6)
692.0 ± 340.7 
(4/10)
495.0 ± 153.0 
(6/4)
PD20AMP  
(mcg)(+/-)
3.8 ± 1.67 
(12/6)
3.5 ± 1.67 
(13/4)
3.2 ± 0.5 
(7/7)
2.6 ± 0.5 
(7/3)
Notes: Values are expressed as mean ± SE. Figures in brackets refer to the number 
of positive and negative provocation tests.
Abbreviations: PD20meth, provocative dose of methacholine required to produce 
a 20% fall in FEV1; PD20AMP, provocative dose of AMP required to produce a 20% 
fall in FEV1.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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Figure 1 Spearman’s rank correlation: ∆FEV1 and sputum neutrophil count in smoking asthmatics (n = 24).
PD20AMP, but not PD20 methacholine, correlated with FEV1/
FVC and FEF25–75, suggesting that PD20AMP provides a bet-
ter reflection of disease severity in smoking related diseases. 
Methacholine acts directly on airway smooth muscle whereas 
AMP is an indirect stimulus that exerts its effect on inflamma-
tory cells, subsequently leading to smooth muscle contraction 
and edema.36 Smoking can stimulate sensory nerve endings 
in the airway wall, which subsequently release tachykinins, 
which in turn can cause smooth muscle contraction via 
  binding to specific cell receptors.37,38 This is a possible path-
way for the effect of AMP in smoking patients. Furthermore, 
tachykinins may enhance hyperresponsiveness via induction 
of airway wall edema and mucus hypersecretion, and possibly 
via induction of smooth muscle hypertrophy resulting from 
chronic stimulation. Moreover, they can induce recruitment 
of inflammatory cells into the airways.36 Therefore, airway 
hyperresponsiveness to AMP provides additional information 
with regard to airway inflammation and disease severity in 
smoking asthmatics and COPD patients.
Surprisingly, in asthmatic patients, no correlation was 
found between AHR and inflammatory cells and mediators. 
AMP mainly acts via the release of mast cell mediators. 
The majority of studies on AMP responsiveness have been 
conducted in allergic patients.39,40
In order to describe the relationship between AHR and 
airway inflammation, excluding the potential confounding 
benefit of steroids, the subjects included were steroid-naive 
patients for at least three months. The absence of inhaled 
steroids, the clinical status (stable disease without symptoms 
for at least three months), and the presence of both atopic and 
non-atopic patients, might explain why we did not observe 
any association between sputum cells and AHR with both 
methacholine and AMP. In support of our findings, data from 
murine models show that AHR appears to be dissociated from 
eosinophilic inflammation.41,42
In COPD patients, a positive correlation between sputum 
neutrophil percentage and AHR was observed, suggest-
ing a role of neutrophils in airway hyperresponsiveness. 
Willemse et al43 studied the effect of smoking cessation on 
sputum inflammation and methacholine and AMP stimuli in 
smoker COPD patients. They showed that smoking cessation 
improved both direct and indirect airway hyperresponsiveness 
and that the number of neutrophils increased after six months 
smoking cessation and increased even more after 12 months International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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smoking cessation. Our results might provide an explana-
tion for these findings. Moreover, Cui et al44 transferred 
Type 1 helper T (Th1) cells into IL-8 RRO mice in order 
to evaluate whether IL-8 plays a role in Th1-induced AHR. 
They found no reduction in AHR. Their study in mice is in 
line with our study in COPD patients, in which AHR cor-
relates with sputum neutrophils, but not with IL-8 levels 
in sputum.
IL-8 sputum levels were statistically significantly higher 
in smoking asthmatics compared to non-smoking asthmat-
ics, and although TNF-α levels were also higher in smoking 
asthmatics, the difference was not significant compared to 
non-smoking asthmatics. IL-8 is a pro-inflammatory media-
tor and a neutrophil chemoattractant.44 However, in stable 
asthma and COPD patients, it is not clear whether IL-8 plays 
a role as a chemoattractant for neutrophils, or as a proinflam-
matory mediator that is released from neutrophils. There 
was no correlation between IL-8 and TNF-α and ∆FEV1 
and AHR. Since we did not find IL-8 to be correlated with 
∆FEV1, it might be suggested that IL-8 acts as an indicator 
of the severity of neutrophilic inflammation, rather than 
as an   indicator of pulmonary function. Finally, IL-8 and 
TNF-α were significantly increased in COPD patients with 
  reversibility, compared to smoking and non-smoking asth-
matics, whereas no difference was found in inflammatory 
cells and cytokines between the COPD groups.
In conclusion, it is evident, that the effect of smoking 
on airway inflammation is important and may influence 
the physiological characteristics of the airways differently 
in asthma and in COPD. Moreover, the different sputum 
inflammatory profile in smoking asthmatics and COPD 
patients, including COPD patients with reversibility, 
provides a role for sputum induction in clinical practice. 
  However, more studies are needed in order for cut off   values 
that differentiate asthma from COPD to be determined. 
Finally, the combination of sputum induction, reversibility, 
and AHR tests might be useful in diagnosing and monitoring 
chronic inflammatory airway diseases, and better managing 
their treatment.
Author contributions
ED and NR carried out the sampling and measurement of 
mediators, participated in the design and statistical analy-
sis, and drafted the manuscript. CG analyzed the ELISAs. 
20,00
0,00
1,00
P
D
2
0
A
M
P
2,00
3,00
4,00
5,00
r = 0.662, P = 0.004
40,00 60,00
Netrophils (%)
80,00 100,00
Figure 2 Spearman’s rank correlation: PD20AMP and sputum neutrophil percentage in COPD patients with reversibility (n = 10) and without reversibility (n = 21).International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
295
Diagnostic tools for asthma and COPD
CGr conceived of the study and participated in its design and 
coordination. CR participated in coordination. All authors 
read and approved the final manuscript.
Disclosure
The authors declare that they have no competing interests.
References
  1.  National Heart Lung and Blood Institute. Expert Panel Report 3: 
Guidelines for the Diagnosis and Management of Asthma. Bethesda: 
MD; 2007. NIH Publication No. 07–4051.
  2.  Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, 
management, and prevention of chronic obstructive pulmonary dis-
ease: GOLD executive summary. Am J Respir Crit Care Med. 2007; 
176:532–555.
  3.  Fabbri LM, Romagnoli M, Corbetta L, et al. Differences in airway 
inflammation in patients with fixed airflow obstruction due to asthma 
or chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 
2003;167:418–424.
  4.  Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive   pulmonary 
disease: molecular and cellular mechanisms. Eur Respir J. 2003; 
22:672–688.
  5.  Braman SS, Kaemmerlen JT, Davis SM. Asthma in the elderly: a 
comparison between patients with recently acquired and long-standing 
disease. Am Rev Respir Dis. 1991;143:336–340.
  6.  Chang J, Mosenifar Z. Differentiating COPD from asthma in clinical 
practice. J Intensive Care Med. 2007;22:300–309.
  7.  Yawn BP. Differential assessment and management of asthma vs chronic 
obstructive pulmonary disease. Medscape J Med. 2009;11(1):20.
  8.  Chaudhuri R, Livingston E, McMahon AD, et al. Cigarette smoking 
impairs the therapeutic response to oral corticosteroids in chronic 
asthma. Am J Respir Crit Care Med. 2003;168:1308–1311.
  9.  Mitsunobu F, Ashida K, Metso T, et al. Influence of long-term 
cigarette smoking on immunoglobin E-mediated allergy, pulmonary 
function, and high-resolution computed tomography lung densi-
tometry in elderly patients with asthma. Clin Exp Allergy. 2004;34: 
59–64.
  10.  Tomlinson JEM, McMahon AD, Chaudhuri R, et al. Efficacy of low 
and high dose inhaled corticosteroid in smokers versus non smokers 
with mild asthma. Thorax. 2005;60:282–287.
  11.  Papi A, Romagnoli M, Baraldo S, et al. Partial reversibility of 
airflow obstruction and increased NO and sputum eosinophilia in 
chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 
2000;162:1773–1777.
  12.  Willemse BW, Postma DS, Timens W, et al. The impact of smoking 
cessation on respiratory symptoms, lung function, airway hyperrespon-
siveness and inflammation. Eur Respir J. 2004;23:464–476.
  13.  Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global 
Strategy for the Diagnosis, Management, and Prevention of Chronic 
Obstructive Pulmonary Disease NHLBI/WHO Workshop report [revised 
edition 2006]. Available from: http://www.goldcopd.com. Accessed 
Nov 25, 2006.
  14.  Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced 
ventilatory flows. Report Working Party Standardization of Lung 
Function Tests, European Community for Steel and Coal. Official 
Statement of the European Respiratory Society. Eur Respir J Suppl. 
1993;16:5–40.
  15.  Calverley PMA, Burge PS, Spencer S, et al. Bronchodilator revers-
ibility testing in chronic obstructive pulmonary disease. Thorax. 
2003;58:659–664.
  16.  Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine 
and exercise challenge testing-1999. Am J Respir Crit Care Med. 
2000;161:309–329.
  17.  Rutgers SR, Timens W, Tzanakis N, et al. Airway inflammation and 
hyperresponsiveness to adenosine 5.-monophosphate in chronic obstruc-
tive pulmonary disease. Clin Exp Allergy. 2000;30:657–662.
  18.  Rutgers SR, Timens W, Kaufmann HF, et al. Comparison of induced 
sputum with bronchial wash, bronchoalveolar lavage and bronchial 
biopsies in COPD. Eur Respir J. 2000;15:109–115.
  19.  Simpson LJ, Scott R, Boyle MJ. Inflammatory subtypes in asthma: 
assessment and identification using induced sputum. Respirology. 
2006;11:54–61.
  20.  Keatings VM, Barnes PJ. Granulocyte activation in induced   sputum: 
comparison between chronic obstructive pulmonary disease, asthma and 
normal subjects. Am J Respir Crit Care Med. 1997;155: 449–453.
  21.  Boulet PL, Lemiere C, Archambault F, et al. Smoking and asthma. 
  Clinical and radiological features, lung function, and airway 
  inflammation. Chest. 2006;129:661–668.
  22.  Chalmers G, MacLeod K, Thomson L, et al. Smoking and airway inflam-
mation in patients with mild asthma. Chest. 2001;120:1917–1922.
  23.  Zhang X, Moilanen E, Lathi A, et al. Regulation of eosinophilic apop-
tosis by nitrice oxide: a role of c-Jun-N-terminal kinase and signal 
transducer and activator of transcription 5. J Allergy Clin Immunol. 
2003;112:93–101.
  24.  Assrey J, Cunha F, Liew F, Moncada S. Feedback inhibition of nitric 
oxide synthase by nitric oxide. Br J Clin Pharmacol. 1993;108: 
833–837.
  25.  Wang H, Yu M, Ocham M, et al. Nicotine acetylocholine receptor 
7 subunit is an essential regulator of inflammation. Nature. 2003;421: 
348–388.
  26.  Sopori M, Kozak W. Immunomodulatory effects of cigarette smoke. 
J Neuroimmunol. 1998;83:148–156.
  27.  Shaw D, Berry M, Mckenna S, et al. Association between neutrophilic 
airway inflammation and airflow limitation in adults with asthma. Chest. 
2007;132:1871–1875.
  28.  Woodruff P, Khashayar R, Lazarus S, et al. Relationship between 
airway inflammation, hyperresponsiveness, and obstruction in asthma. 
J Allergy Clin Immunol. 2001;108:753–758.
  29.  Little SA, MacLeod KJ, Chalmers GW, et al. Association of forced 
expiratory volume with disease duration and sputum neutrophils in 
chronic asthma. Am J Med. 2002;112:446–452.
  30.  Takayma K, Augusti C, Ueki I, et al. Neutrophilic dependent goblet 
cell degranulation: role of membrane-bound elastase and adhesion 
molecules. Am J Physiol. 1998;275:L294–L302.
  31.  Nadel JA, Takeyama K, Austi C. Role of neutrophil elastase in hyper-
secretion in asthma. Eur Respir J. 1999;13:190–196.
  32.  Amitani R, Wilson R, Rutman A, et al. Effects of human neutrophil 
elastase and Pseudomonas aeruginosa proteinases on human respiratory 
epithelium. Am J Respir Crit Care Med. 1991;1:26–32.
  33.  Gross NJE, Skorodin MS. Cholinergic bronchomotor tone in COPD: 
estimates of its amount in comparison with that in normal subjects. 
Chest. 1989;96:984–987.
  34.  Ichinose M, Takahashi T, Suguira H, et al. Baseline hyperresponsiveness 
and its reversible component: role of inflammation and airway caliber. 
Eur Respir J. 2000;15:248–253.
  35.  Kuwano K, Bosken CH, Pare PD, et al. Small airways dimensions in 
asthma and in chronic obstructive pulmonary disease. Am Rev Respir 
Dis. 1993;148:1220–1225.
  36.  Lambert RK, Wiggs BR, Kumano K, et al. Functional significance of 
increased airway smooth muscle in asthma and COPD. J Appl Physiol. 
1993;74:2771–2781.
  37.  Van Schoor J, Joos GF, Pawels RA. Indirect bronchial hyperresponsive-
ness in asthma: mechanism, pharmacology and implication for clinical 
research. Eur Respir J. 2000;16:514–513.
  38.  Barnes PJ. Neurogenic inflammation in airways. Int Arch Allergy Appl 
Immunol. 1991;94:303–309.
  39.  Hong JL, Rodge IW, Lee LY. Cigarette smoke-induced bronchoconstric-
tion: cholinergic mechanisms, tachykinins, and cycloxygenase products. 
J Appl Physiol. 1995;78:2260–2266.International Journal of COPD
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-copd-journal
The International Journal of COPD is an international, peer-reviewed 
journal of therapeutics and pharmacology focusing on concise rapid 
reporting of clinical studies and reviews in COPD. Special focus is given 
to the pathophysiological processes underlying the disease, intervention 
programs, patient focused education, and self management protocols. 
This journal is indexed on PubMed Central, MedLine and CAS. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
296
Dima et al
  40.  Meer de G, Heederik D, Postma DS. Bronchial responsiveness to 
adenosine 5’-monophosphate (AMP) and methacholine differ in their 
relationship with airway allergy and baseline FEV1. Am J Crit Care 
Med. 2002;165:327–331.
  41.  Van de Berge M, Meijer JR, Kerstjens HAM, et al. PC20 adenosine 
5’-monophosphate is more closely associated with airway inflamma-
tion in asthma than PC20 methacholine. Am J Crit Care Med. 2001;163: 
1546–1550.
  42.  Corry BD, Folkesson HG, Warnock ML, et al. Interleukine 4, but not 
interleukine 5 or eosinophils, is required in a murine model of acute 
airway hyperreactivity. J Exp Med. 1996;183:109–117.
  43.  Willemse BWM, ten Hacken NHT, Rutgers B, et al. Smoking   cessation 
improves both direct and indirect airway hyperresponsiveness in COPD. 
Eur Respir J. 2004;24:391–396.
  44.  Cui J, Pazddziorko S, Miyashiro P, et al. Th1-mediated airway hyper-
resposiveness independent of neutrophilic inflammation. J Allergy Clin 
Immunol. 2005;115:309–315.